Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    February 2024
  1. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    PubMed    


  2. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    PubMed    


    December 2023
  3. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    PubMed    


  4. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    PubMed    


    November 2023
  5. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    PubMed    


    September 2023
  6. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    PubMed    


  7. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    


  8. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    


    August 2023
  9. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    


    July 2023
  10. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    


  11. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    


  12. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available


  13. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    


  14. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    


  15. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    


  16. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    


  17. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    


    June 2023
  18. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    


  19. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    


    May 2023
  20. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    


  21. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    


    March 2023
  22. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    


    February 2023
  23. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    


  24. LE GUEN Y, Raulin AC, Logue MW, Sherva R, et al
    Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    JAMA. 2023;329:551-560.
    PubMed     Abstract available


    January 2023
  25. LARKIN HD
    Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    JAMA. 2023 Jan 18. doi: 10.1001/jama.2022.24490.
    PubMed    


  26. LARKIN H
    Noninvasive Sensory Stimulation With Light and Sound Tested in Alzheimer Disease.
    JAMA. 2023;329:114.
    PubMed    


    September 2022
  27. HARRIS E
    Large Autopsy Study Estimates Prevalence of "LATE" Neuropathologic Change.
    JAMA. 2022;328:815-816.
    PubMed    


    August 2022
  28. RUBIN R
    Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches.
    JAMA. 2022 Aug 17. pii: 2795592. doi: 10.1001/jama.2022.11490.
    PubMed    


  29. DEPEW R
    To My Husband With Alzheimer Disease.
    JAMA. 2022;328:587.
    PubMed    


  30. SLOMSKI A
    Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease.
    JAMA. 2022;328:415.
    PubMed    


    July 2022
  31. SURAN M
    Some Antioxidants May Mitigate the Risk of Dementias.
    JAMA. 2022;328:321.
    PubMed    


    June 2022
  32. RUBIN R
    New Test to Help Diagnose Alzheimer Disease.
    JAMA. 2022;327:2281.
    PubMed    


    May 2022
  33. LARKIN HD
    First Donepezil Transdermal Patch Approved for Alzheimer Disease.
    JAMA. 2022;327:1642.
    PubMed    


    December 2021
  34. SLOMSKI A
    Methylphenidate Treats Apathy in Alzheimer Disease.
    JAMA. 2021;326:2120.
    PubMed    


    October 2021
  35. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    


    September 2021
  36. ANDERSON TS, Ayanian JZ, Souza J, Landon BE, et al
    Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    JAMA. 2021 Sep 9. pii: 2784225. doi: 10.1001/jama.2021.15286.
    PubMed    


    August 2021
  37. RUBIN R
    CMS Considers Controversial Alzheimer Drug Coverage.
    JAMA. 2021;326:690.
    PubMed    


    July 2021
  38. RUBIN R
    Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    JAMA. 2021 Jul 21. pii: 2782427. doi: 10.1001/jama.2021.11558.
    PubMed    


  39. SCHULMAN KA, Greicius MD, Richman B
    Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    JAMA. 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.
    PubMed    


    June 2021
  40. CHEN MH, Yang FC, Liang CS
    APOE Allele Testing and Alzheimer Disease.
    JAMA. 2021;325:2210-2211.
    PubMed    


  41. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE Allele Testing and Alzheimer Disease-Reply.
    JAMA. 2021;325:2211.
    PubMed    


    April 2021
  42. RUBIN R
    Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease.
    JAMA. 2021 Apr 28. pii: 2779452. doi: 10.1001/jama.2021.5333.
    PubMed    


    March 2021
  43. ALEXANDER GC, Emerson S, Kesselheim AS
    Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    JAMA. 2021 Mar 30. pii: 2778191. doi: 10.1001/jama.2021.3854.
    PubMed    


    January 2021
  44. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE varepsilon4 Allele Testing and Risk of Alzheimer Disease.
    JAMA. 2021 Jan 14. pii: 2775399. doi: 10.1001/jama.2020.15085.
    PubMed    


    November 2020
  45. MADDOX M
    Alzheimer Aubade.
    JAMA. 2020;324:2108.
    PubMed    


    October 2020
  46. TSOU AY, Bulova P, Capone G, Chicoine B, et al
    Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    JAMA. 2020;324:1543-1556.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.